Literature DB >> 32926565

Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.

Celalettin Ustun1,2, Elizabeth A Morgan3, Ethan M Ritz4, Hanne Vestergaard5, Sheeja Pullarkat6, Philip M Kluin7, Robert Ohgami8, Linda B Baughn9, Young Kim10, Nam K Ku6, David Czuchlewski11, Michael Boe Møller5,12,13, Ana-Iris Schiefer14, Krzysztof Mrózek15, Hans-Peter Horny16, Tracy I George11,17, Thomas Kielsgaard Kristensen12,18, Todd Beck4, Sunita Nathan1, Cecilia Arana Yi11, Cecilia Yeung19,20, Vinod Pullarkat21, Jason Gotlib22, Cem Akin23, Jessica Kohlschmidt15,24, Amandeep Salhotra10, Lori Soma20, Dong Chen9, Se Y Han2, Christina Cho25,26, Wolfgang Sperr27, Sigurd Broesby-Olsen13,28, Michael A Linden29, Michelle Dolan29, Gregor Hoermann30, Jason L Hornick3, Clara Bloomfield15, Ryo Nakamura21, H Joachim Deeg19,20, Mark R Litzow31, Gautam Borthakur32, Daniel Weisdorf2, Gerwin Huls33, Miguel-Angel Perales26, Peter Valent27, Guido Marcucci21.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32926565      PMCID: PMC8434847          DOI: 10.1111/ijlh.13338

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


× No keyword cloud information.
  12 in total

1.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.

Authors:  Hendrik J M de Jonge; Peter J M Valk; Eveline S J M de Bont; Jan Jacob Schuringa; Gert Ossenkoppele; Edo Vellenga; Gerwin Huls
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 3.  Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.

Authors:  Celalettin Ustun; Guido Marcucci
Journal:  Curr Opin Hematol       Date:  2015-03       Impact factor: 3.284

4.  Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Authors:  Federico Mosna; Cristina Papayannidis; Giovanni Martinelli; Eros Di Bona; Angela Bonalumi; Cristina Tecchio; Anna Candoni; Debora Capelli; Andrea Piccin; Fabio Forghieri; Catia Bigazzi; Giuseppe Visani; Renato Zambello; Lucia Zanatta; Francesca Volpato; Stefania Paolini; Nicoletta Testoni; Filippo Gherlinzoni; Michele Gottardi
Journal:  Am J Hematol       Date:  2015-04-01       Impact factor: 10.047

Review 5.  Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.

Authors:  J F Seymour; S K Juneja; L J Campbell; P H Ellims; E H Estey; H M Prince
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

6.  Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.

Authors:  G Martín; E Barragán; P Bolufer; C Chillón; R García-Sanz; T Gómez; S Brunet; M González; M A Sanz
Journal:  Haematologica       Date:  2000-07       Impact factor: 9.941

7.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Authors:  R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

8.  Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Authors:  Peter Paschka; Juan Du; Richard F Schlenk; Verena I Gaidzik; Lars Bullinger; Andrea Corbacioglu; Daniela Späth; Sabine Kayser; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Claus-Henning Köhne; Gerhard Held; Marie von Lilienfeld-Toal; Heinz Kirchen; Mathias Rummel; Katharina Götze; Heinz-August Horst; Mark Ringhoffer; Michael Lübbert; Mohammed Wattad; Helmut R Salih; Andrea Kündgen; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2012-10-31       Impact factor: 22.113

9.  Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Authors:  Celalettin Ustun; Elizabeth Morgan; Erica E M Moodie; Sheeja Pullarkat; Cecilia Yeung; Sigurd Broesby-Olsen; Robert Ohgami; Young Kim; Wolfgang Sperr; Hanne Vestergaard; Dong Chen; Philip M Kluin; Michelle Dolan; Krzysztof Mrózek; David Czuchlewski; Hans-Peter Horny; Tracy I George; Thomas Kielsgaard Kristensen; Nam K Ku; Cecilia Arana Yi; Michael Boe Møller; Guido Marcucci; Linda Baughn; Ana-Iris Schiefer; J R Hilberink; Vinod Pullarkat; Ryan Shanley; Jessica Kohlschmidt; Janie Coulombe; Amandeep Salhotra; Lori Soma; Christina Cho; Michael A Linden; Cem Akin; Jason Gotlib; Gregor Hoermann; Jason Hornick; Ryo Nakamura; Joachim Deeg; Clara D Bloomfield; Daniel Weisdorf; Mark R Litzow; Peter Valent; Gerwin Huls; Miguel-Angel Perales; Gautam Borthakur
Journal:  Cancer Med       Date:  2018-08-16       Impact factor: 4.452

10.  Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.

Authors:  Montserrat Hoyos; Josep F Nomdedeu; Jordi Esteve; Rafael Duarte; Josep M Ribera; Andreu Llorente; Lourdes Escoda; Javier Bueno; Mar Tormo; David Gallardo; Maria Paz Queipo de Llano; Josep M Martí; Anna Aventín; Ramón Mangues; Salut Brunet; Jorge Sierra
Journal:  Eur J Haematol       Date:  2013-07-25       Impact factor: 3.674

View more
  3 in total

Review 1.  Emerging therapies for inv(16) AML.

Authors:  Sridevi Surapally; Daniel G Tenen; John A Pulikkan
Journal:  Blood       Date:  2021-05-13       Impact factor: 22.113

2.  Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.

Authors:  Lianjun Zhang; Le Xuan Truong Nguyen; Ying-Chieh Chen; Dijiong Wu; Guerry J Cook; Dinh Hoa Hoang; Casey J Brewer; Xin He; Haojie Dong; Shu Li; Man Li; Dandan Zhao; Jing Qi; Wei-Kai Hua; Qi Cai; Emily Carnahan; Wei Chen; Xiwei Wu; Piotr Swiderski; Russell C Rockne; Marcin Kortylewski; Ling Li; Bin Zhang; Guido Marcucci; Ya-Huei Kuo
Journal:  Nat Commun       Date:  2021-10-22       Impact factor: 14.919

3.  Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia.

Authors:  Yan Mao; Jinwen Xu; Xuejiao Xu; Jiayun Qiu; Zhengyun Hu; Feng Jiang; Guoping Zhou
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.